Skip to content

C.E Pharma: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

C.E Pharma

BE 0793.409.817
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€17,197
2024 · -€22,691+€5,494
Equity
-€46,167
2024 · -€28,970-€17,197
Cash
€10,222
2024 · -+€10,222
Balance sheet total
€263,031
2024 · €336,365-€73,333

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€40,645

    down €40,645 (-50.9%), from €79,778 to €39,133

    of which Trade receivables: -€33,380

  • Intangible fixed assets -€30,000

    down €30,000 (-33.1%), from €90,575 to €60,575

  • Current investments -€13,996

    no longer reported in 2025 (was €13,996)

  • Cash +€10,222

    new in 2025: €10,222

    mainly Receivables within one year (+€40,645) and Depreciation (+€40,232)

  • Stocks and contracts +€7,105

    up €7,105 (+18.4%), from €38,634 to €45,739

Equity and liabilities
  • Trade debts -€38,150

    down €38,150 (-42.3%), from €90,286 to €52,136

  • Debts after one year -€18,248

    down €18,248 (-8.0%), from €228,374 to €210,125

  • Profit (loss) carried forward -€17,197

    down €17,197 (-44.1%), from -€38,970 to -€56,167

  • Other debts -€9,407

    down €9,407 (-42.2%), from €22,285 to €12,878

  • Tax, wage and social debts +€8,585

    up €8,585 (+143.8%), from €5,971 to €14,556

    of which Remuneration and social security: +€7,388

Income statement
  • Gross operating margin +€24,208

    up €24,208 (+29.6%), from €81,911 to €106,119

  • Staff costs +€18,632

    up €18,632 (+37.7%), from €49,481 to €68,113

  • Other operating charges -€5,219

    down €5,219 (-83.7%), from €6,236 to €1,017

  • Financial charges +€2,272

    up €2,272 (+22.7%), from €10,006 to €12,279

  • Taxes +€1,942

    new in 2025: €1,942

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 -€22,691
Gross operating margin +€24,208
Staff costs -€18,632
Depreciation -€1,330
Other operating charges +€5,219
Financial income +€244
Financial charges -€2,272
Taxes -€1,942
Result 2025 -€17,197

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€17,131
Investment +€10,255
Financing -€17,164
Cash 2024 €0
Net result for the year -€17,197
Depreciation +€40,232
Stocks and contracts -€7,105
Receivables within one year +€40,645
Deferred charges and accrued income -€472
Trade debts -€38,150
Tax, wage and social debts +€8,585
Other debts -€9,407
Investment in fixed assets (net) -€3,741
Current investments +€13,996
Debts after one year -€18,248
Current portion of long-term debt +€1,084
Cash 2025 €10,222
Every line side by side 44 lines
Line Code 2024 2025 Change %
Total assets 20/58 €336,365 €263,031 -€73,333 -21.8%
Fixed assets 21/28 €203,957 €167,465 -€36,492 -17.9%
Intangible fixed assets 21 €90,575 €60,575 -€30,000 -33.1%
Tangible fixed assets 22/27 €113,271 €106,779 -€6,492 -5.7%
Land and buildings 22 €94,029 €91,198 -€2,831 -3.0%
Furniture and vehicles 24 €19,242 €15,581 -€3,661 -19.0%
Financial fixed assets 28 €111 €111 = 0.0%
Current assets 29/58 €132,408 €95,566 -€36,842 -27.8%
Stocks and contracts in progress 3 €38,634 €45,739 +€7,105 +18.4%
Stocks 30/36 €38,634 €45,739 +€7,105 +18.4%
Amounts receivable within one year 40/41 €79,778 €39,133 -€40,645 -50.9%
Trade receivables 40 €72,335 €38,955 -€33,380 -46.1%
Other amounts receivable 41 €7,444 €178 -€7,266 -97.6%
Current investments 50/53 €13,996 - -€13,996
Cash at bank and in hand 54/58 - €10,222 +€10,222
Deferred charges and accrued income 490/1 - €472 +€472
Total equity and liabilities 10/49 €336,365 €263,031 -€73,333 -21.8%
Equity 10/15 -€28,970 -€46,167 -€17,197 -59.4%
Contributions 10/11 €10,000 €10,000 = 0.0%
Profit (loss) carried forward 14 -€38,970 -€56,167 -€17,197 -44.1%
Amounts payable 17/49 €365,335 €309,199 -€56,136 -15.4%
Amounts payable after more than one year 17 €228,374 €210,125 -€18,248 -8.0%
Financial debts 170/4 €228,374 €210,125 -€18,248 -8.0%
Amounts payable within one year 42/48 €136,961 €99,073 -€37,888 -27.7%
Current portion of amounts payable after more than one year 42 €18,419 €19,503 +€1,084 +5.9%
Trade debts 44 €90,286 €52,136 -€38,150 -42.3%
Suppliers 440/4 €90,286 €52,136 -€38,150 -42.3%
Taxes, remuneration and social security 45 €5,971 €14,556 +€8,585 +143.8%
Taxes 450/3 €2,593 €3,790 +€1,197 +46.2%
Remuneration and social security 454/9 €3,378 €10,766 +€7,388 +218.7%
Other amounts payable 47/48 €22,285 €12,878 -€9,407 -42.2%
Remuneration, social security and pensions 62 €49,481 €68,113 +€18,632 +37.7%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €38,902 €40,232 +€1,330 +3.4%
Other operating charges 640/8 €6,236 €1,017 -€5,219 -83.7%
Gross operating margin 9900 €81,911 €106,119 +€24,208 +29.6%
Operating profit (loss) 9901 -€12,708 -€3,243 +€9,465 +74.5%
Financial income 75/76B €23 €268 +€244 +1043.1%
Recurring financial income 75 €23 €268 +€244 +1043.1%
Financial charges 65/66B €10,006 €12,279 +€2,272 +22.7%
Recurring financial charges 65 €10,006 €12,279 +€2,272 +22.7%
Profit (loss) for the period before taxes 9903 -€22,691 -€15,254 +€7,437 +32.8%
Income taxes 67/77 - €1,942 +€1,942
Profit (loss) for the period 9904 -€22,691 -€17,197 +€5,494 +24.2%
Profit (loss) for the period to be appropriated 9905 -€22,691 -€17,197 +€5,494 +24.2%

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 September 2026 via checked.be.